S&P 500   5,087.03
DOW   39,069.11
QQQ   438.07
Top-Rated AMD nears major breakout level
66,000% upside on tiny biotech? (Ad)
Roku stock and the mother of all entry opportunities
AI powerhouse NVIDIA will hit $1000 soon
66,000% upside on tiny biotech? (Ad)
Nvidia, Royal Caribbean rise; Rivian, Etsy fall, Thursday, 2/22/2024
Rivian shares gets discounted; shares can move lower 
66,000% upside on tiny biotech? (Ad)
The Trade Desk: 3 reasons to buy before a new all-time high
Wall Street sees a solid year ahead for homebuilders, though mortgage rates remain a wildcard
S&P 500   5,087.03
DOW   39,069.11
QQQ   438.07
Top-Rated AMD nears major breakout level
66,000% upside on tiny biotech? (Ad)
Roku stock and the mother of all entry opportunities
AI powerhouse NVIDIA will hit $1000 soon
66,000% upside on tiny biotech? (Ad)
Nvidia, Royal Caribbean rise; Rivian, Etsy fall, Thursday, 2/22/2024
Rivian shares gets discounted; shares can move lower 
66,000% upside on tiny biotech? (Ad)
The Trade Desk: 3 reasons to buy before a new all-time high
Wall Street sees a solid year ahead for homebuilders, though mortgage rates remain a wildcard
S&P 500   5,087.03
DOW   39,069.11
QQQ   438.07
Top-Rated AMD nears major breakout level
66,000% upside on tiny biotech? (Ad)
Roku stock and the mother of all entry opportunities
AI powerhouse NVIDIA will hit $1000 soon
66,000% upside on tiny biotech? (Ad)
Nvidia, Royal Caribbean rise; Rivian, Etsy fall, Thursday, 2/22/2024
Rivian shares gets discounted; shares can move lower 
66,000% upside on tiny biotech? (Ad)
The Trade Desk: 3 reasons to buy before a new all-time high
Wall Street sees a solid year ahead for homebuilders, though mortgage rates remain a wildcard
S&P 500   5,087.03
DOW   39,069.11
QQQ   438.07
Top-Rated AMD nears major breakout level
66,000% upside on tiny biotech? (Ad)
Roku stock and the mother of all entry opportunities
AI powerhouse NVIDIA will hit $1000 soon
66,000% upside on tiny biotech? (Ad)
Nvidia, Royal Caribbean rise; Rivian, Etsy fall, Thursday, 2/22/2024
Rivian shares gets discounted; shares can move lower 
66,000% upside on tiny biotech? (Ad)
The Trade Desk: 3 reasons to buy before a new all-time high
Wall Street sees a solid year ahead for homebuilders, though mortgage rates remain a wildcard
NASDAQ:CLBT

Cellebrite DI (CLBT) Stock Price, News & Analysis

$11.70
+0.49 (+4.37%)
(As of 02/22/2024 ET)
Today's Range
$11.32
$11.80
50-Day Range
$8.04
$11.70
52-Week Range
$5.22
$11.92
Volume
1.86 million shs
Average Volume
926,479 shs
Market Capitalization
$2.38 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$11.00

Cellebrite DI MarketRank™ Stock Analysis

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
6.0% Downside
$11.00 Price Target
Short Interest
Bearish
5.23% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.56mentions of Cellebrite DI in the last 14 days
Based on 14 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
28.13%
From $0.32 to $0.41 Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

0.66 out of 5 stars

Business Services Sector

266th out of 298 stocks

Prepackaged Software Industry

175th out of 189 stocks


CLBT stock logo

About Cellebrite DI Stock (NASDAQ:CLBT)

Cellebrite DI Ltd. develops solutions for legally sanctioned investigations in Europe, the Middle East, Africa, the United States, and the Asia-Pacific. Its DI suite of solutions allows users to collect, review, analyze, and manage digital data across the investigative lifecycle with respect to legally sanctioned investigations and solutions are used in a various case, including child exploitation, homicide, anti-terror, border control, sexual crimes, human trafficking, corporate security, intellectual property theft, and civil litigation. The company's Universal Forensic Extraction Device solution addresses problems in accessing digital information, including complicated device locks, encryption barriers, deleted and unknown content, and other obstacles that can prevent critical evidence from coming to light. It also offers Cellebrite Pathfinder helps investigators reach conclusions faster through automated data ingestion, normalization, consolidation, and visualization of a suspects' journey; CryptoCurrency Investigative Solutions, which analyze blockchain transactions together with related data from an extensive list of sources to identify and categorize wallets and transactions; and OSINT Investigate solution used to search, resolve, and enrich identifiers in open sources. In addition, the company provides Cellebrite Guardian, a cloud-based digital investigative data and evidence management SaaS solution that allows users to manage, store, share, and review investigative data and evidence from intake to creation of a final report; and Commander solution that enables collaboration across investigation functions to reduce manual processes. It serves federal and state and local agencies, as well as enterprise companies and service providers. The company was incorporated in 1999 and is based in Petah Tikva, Israel. Cellebrite Mobile Synchronization Ltd. is a subsidiary of Sun Corporation.

CLBT Stock Price History

CLBT Stock News Headlines

Critical asset just had biggest fall on record
What many consider America's critical financial asset suffers biggest fall on record. Expert says: "it's very bad for millions, protect yourself now."
Cellebrite DI (NASDAQ:CLBT) Raised to "Buy" at Bank of America
Critical asset just had biggest fall on record
What many consider America's critical financial asset suffers biggest fall on record. Expert says: "it's very bad for millions, protect yourself now."
Cellebrite DI (NASDAQ:CLBT) Shares Gap Up Following Analyst Upgrade
William Blair Keeps Their Hold Rating on Cellebrite DI (CLBT)
Cellebrite (CLBT) Benefitting from Increased Data Volume
Cellebrite Announces Fourth-Quarter 2023 Results
Cellebrite Announces Fourth-Quarter 2023 Results
Cellebrite: Growth, Profits, And Consistency
Cellebrite DI (CLBT) to Release Quarterly Earnings on Thursday
See More Headlines
Receive CLBT Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Cellebrite DI and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
11/14/2023
Today
2/22/2024
Next Earnings (Estimated)
5/08/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Industry
Prepackaged software
Sub-Industry
N/A
Current Symbol
NASDAQ:CLBT
Employees
1,005
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$11.00
High Stock Price Target
$13.00
Low Stock Price Target
$9.00
Potential Upside/Downside
-6.0%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
4 Analysts

Profitability

Net Income
$-81,100,000.00
Pretax Margin
-23.24%

Debt

Sales & Book Value

Annual Sales
$325.11 million
Cash Flow
$0.28 per share
Book Value
$0.18 per share

Miscellaneous

Free Float
177,793,000
Market Cap
$2.21 billion
Optionable
Optionable
Beta
1.44

Growth stocks offer a lot of bang for your buck, and we've got the next upcoming superstars to strongly consider for your portfolio.

Get This Free Report

Key Executives

  • Mr. Yossi Carmil (Age 56)
    Founder, CEO & Director
    Comp: $946k
  • Ms. Dana Gerner (Age 57)
    Chief Financial Officer
    Comp: $477k
  • Mr. Leeor Ben-Peretz (Age 48)
    Chief Strategy Officer
    Comp: $416k
  • Mr. Marque Teegardin (Age 58)
    President of Cellebrite Americas - Sales Management
    Comp: $868.71k
  • Mr. Thomas E. Hogan (Age 65)
    Executive Chairman
  • Mr. Arnon Zilberman
    Executive Vice President of Information Systems & Operations
  • Mr. Ronnen Armon (Age 61)
    Chief Products & Technologies Officer
  • Andrew Kramer
    Vice President of Investor Relations
  • Ms. Ayala Berler Shapira
    General Counsel
  • Ms. Lisa Cole (Age 50)
    Chief Marketing Officer














CLBT Stock Analysis - Frequently Asked Questions

Should I buy or sell Cellebrite DI stock right now?

4 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Cellebrite DI in the last twelve months. There are currently 4 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" CLBT shares.
View CLBT analyst ratings
or view top-rated stocks.

What is Cellebrite DI's stock price target for 2024?

4 Wall Street analysts have issued 1 year price targets for Cellebrite DI's stock. Their CLBT share price targets range from $9.00 to $13.00. On average, they anticipate the company's share price to reach $11.00 in the next twelve months. This suggests that the stock has a possible downside of 6.0%.
View analysts price targets for CLBT
or view top-rated stocks among Wall Street analysts.

How have CLBT shares performed in 2024?

Cellebrite DI's stock was trading at $8.66 at the start of the year. Since then, CLBT shares have increased by 35.1% and is now trading at $11.70.
View the best growth stocks for 2024 here
.

Are investors shorting Cellebrite DI?

Cellebrite DI saw a increase in short interest during the month of January. As of January 31st, there was short interest totaling 2,660,000 shares, an increase of 7.7% from the January 15th total of 2,470,000 shares. Based on an average daily trading volume, of 873,700 shares, the days-to-cover ratio is currently 3.0 days. Approximately 5.2% of the company's stock are sold short.
View Cellebrite DI's Short Interest
.

When is Cellebrite DI's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, May 8th 2024.
View our CLBT earnings forecast
.

How were Cellebrite DI's earnings last quarter?

Cellebrite DI Ltd. (NASDAQ:CLBT) posted its quarterly earnings data on Tuesday, November, 14th. The company reported $0.09 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.01 by $0.08. The business earned $84.20 million during the quarter, compared to the consensus estimate of $82.13 million. Cellebrite DI had a positive trailing twelve-month return on equity of 173.14% and a negative net margin of 24.94%. Cellebrite DI's revenue for the quarter was up 17.4% compared to the same quarter last year. During the same period in the previous year, the business posted ($0.01) earnings per share.

What ETFs hold Cellebrite DI's stock?

ETFs with the largest weight of Cellebrite DI (NASDAQ:CLBT) stock in their portfolio include ARK Israel Innovative Technology ETF (IZRL).Amplify BlueStar Israel Technology ETF (ITEQ).

What guidance has Cellebrite DI issued on next quarter's earnings?

Cellebrite DI updated its first quarter 2024 earnings guidance on Friday, February, 16th. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $83.0 million-$88.0 million, compared to the consensus revenue estimate of $84.3 million.

Who are Cellebrite DI's major shareholders?

Cellebrite DI's stock is owned by a number of institutional and retail investors. Top institutional investors include IGP Investments G.P.L.P LP (11.18%), Clal Insurance Enterprises Holdings Ltd (3.76%), Crosslink Capital Inc. (1.72%), Greenhaven Road Investment Management L.P. (1.52%), Voss Capital LLC (0.97%) and Ashford Capital Management Inc. (0.79%).

How do I buy shares of Cellebrite DI?

Shares of CLBT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:CLBT) was last updated on 2/23/2024 by MarketBeat.com Staff